These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 14706214)

  • 21. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myasthenia gravis in Jamaican children: a 12-year institutional review.
    Melbourne Chambers R; Forrester S; Gray R; Tapper J; Trotman H
    Paediatr Int Child Health; 2012 Feb; 32(1):47-50. PubMed ID: 22525448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
    Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis for the effect of different regimens on ocular myasthenia gravis in children].
    Liu C; Wang X; Xie L; Peng J; Wu L; Zheng X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1275-1279. PubMed ID: 29187654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.
    Bi Z; Ge H; Zhang Q; Gao H; Yang M; Zhan J; Lin J; Gui M; Li Y; Ji S; Cao Y; Bu B
    Pediatr Neurol; 2023 Sep; 146():31-39. PubMed ID: 37421800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China.
    Ding J; Zhao S; Ren K; Dang D; Li H; Wu F; Zhang M; Li Z; Guo J
    BMC Neurol; 2020 Jun; 20(1):238. PubMed ID: 32527235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
    Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
    Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term prednisone followed by thymectomy in myasthenia gravis.
    Mann JD; Johns TR; Campa JF; Muller WH
    Ann N Y Acad Sci; 1976; 274():608-22. PubMed ID: 1066998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
    Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
    JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular myasthenia gravis patients following the administration of tacrolimus and steroids.
    Omata T; Fukui K; Kodama K; Watanabe Y; Aoyama H; Fujii K; Shimojo N
    J Neurol Sci; 2019 Jan; 396():30-32. PubMed ID: 30399462
    [No Abstract]   [Full Text] [Related]  

  • 32. Myasthenia gravis and return to flying status.
    Karmon Y; Blum S; Levite R; Barenboim E; Gadoth N
    Aviat Space Environ Med; 2010 Jan; 81(1):69-73. PubMed ID: 20058740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic options in ocular myasthenia gravis.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    Neuromuscul Disord; 2001 Mar; 11(2):208-16. PubMed ID: 11257479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
    Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low conversion rate of ocular to generalized myasthenia gravis in Singapore.
    Teo KY; Tow SL; Haaland B; Gosavi TD; Jing-Liang L; Yew Long LO; Milea D
    Muscle Nerve; 2018 May; 57(5):756-760. PubMed ID: 28981152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical and surgical treatment for ocular myasthenia.
    Benatar M; Kaminski H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005081. PubMed ID: 16625623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkinson's disease associated with myasthenia gravis. A report of 4 cases.
    Levin N; Karussis D; Abramsky O
    J Neurol; 2003 Jun; 250(6):766-7. PubMed ID: 12862037
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of ocular symptoms in myasthenia gravis.
    Bhanushali MJ; Wuu J; Benatar M
    Neurology; 2008 Oct; 71(17):1335-41. PubMed ID: 18936425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Mummy, my eyelids are heavy": A case series of juvenile myasthenia gravis.
    Krishna L; Abdul Jalil NF; Lott PW; Singh S; Choo MM
    Eur J Ophthalmol; 2021 Mar; 31(2):NP119-NP122. PubMed ID: 31390886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myasthenia gravis in children: analysis of 18 patients.
    Morita MP; Gabbai AA; Oliveira AS; Penn AS
    Arq Neuropsiquiatr; 2001 Sep; 59(3-B):681-5. PubMed ID: 11593264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.